Who Paid My Doc
Esperoct
Biological Hemophilia
NDC 0169-8500-01
General payments
$534,301
Research payments
$1,891,105
Through program year 2025, $534,301 in general payments and $1,891,105 in research payments were reported against Esperoct (Hemophilia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $175 | 10 |
| 2024 | General | $116,879 | 151 |
| 2024 | Research | $197,104 | 7 |
| 2023 | General | $63,515 | 62 |
| 2023 | Research | $649,936 | 10 |
| 2022 | General | $115,715 | 151 |
| 2022 | Research | $154,007 | 53 |
| 2021 | General | $76,906 | 116 |
| 2021 | Research | $403,293 | 178 |
| 2020 | General | $161,111 | 138 |
| 2020 | Research | $486,765 | 417 |
Breakdown
The top 5 of 10 recipients; each share is of general payments naming this product in 2025.
The top 5 of 8 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
628 general · 665 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.